Cargando…

GLP2-2G-XTEN: A Pharmaceutical Protein with Improved Serum Half-Life and Efficacy in a Rat Crohn’s Disease Model

OBJECTIVES: Glucagon-like peptide 2 (GLP2) is an intestinal growth factor that has been shown to stimulate intestinal growth and reduce disease severity in preclinical models of short bowel syndrome and inflammatory bowel disease. Teduglutide, a recombinant human GLP2 variant (GLP2-2G), has increase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alters, Susan E., McLaughlin, Bryant, Spink, Benjamin, Lachinyan, Tigran, Wang, Chia-wei, Podust, Vladimir, Schellenberger, Volker, Stemmer, Willem P. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3506575/ https://www.ncbi.nlm.nih.gov/pubmed/23189208 http://dx.doi.org/10.1371/journal.pone.0050630

Ejemplares similares

Correction: GLP2-2G-XTEN: A Pharmaceutical Protein with Improved Serum Half-Life and Efficacy in a Rat Crohn’s Disease Model
por: Alters, Susan E., et al.
Publicado: (2013)

Multivalent Antiviral XTEN–Peptide Conjugates with Long in Vivo Half-Life and Enhanced Solubility
por: Ding, Sheng, et al.
Publicado: (2014)

Gcg-XTEN: An Improved Glucagon Capable of Preventing Hypoglycemia without Increasing Baseline Blood Glucose
por: Geething, Nathan C., et al.
Publicado: (2010)

A Novel Long-Acting Human Growth Hormone Fusion Protein (VRS-317): Enhanced In Vivo Potency and Half-Life
por: Cleland, Jeffrey L, et al.
Publicado: (2012)

XTEN as Biological Alternative to PEGylation Allows Complete Expression of a Protease-Activatable Killin-Based Cytostatic
por: Haeckel, Akvile, et al.
Publicado: (2016)

Long-circulating XTEN864-annexin A5 fusion protein for phosphatidylserine-related therapeutic applications
por: Haeckel, Akvile, et al.
Publicado: (2021)

A homogeneous high-DAR antibody–drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides
por: Zacharias, Neelie, et al.
Publicado: (2022)

Cardioprotective effects of GLP‐1(28‐36a): A degraded metabolite or GLP‐1’s better half?
por: Liu, Yangyang, et al.
Publicado: (2020)

Polymorphisms of GLP-1 Receptor Gene and Response to GLP-1 Analogue in Patients with Poorly Controlled Type 2 Diabetes
por: Lin, Chia-Hung, et al.
Publicado: (2015)

Purslane Effect on GLP-1 and GLP-1 receptor in type 2 diabetes
por: Heidarzadeh, Sara, et al.
Publicado: (2013)

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men
por: Matikainen, Niina, et al.
Publicado: (2016)

GLP-1 and GLP-2 as Yin and Yang of Intestinal Lipoprotein Production: Evidence for Predominance of GLP-2–Stimulated Postprandial Lipemia in Normal and Insulin-Resistant States
por: Hein, Gustavo J., et al.
Publicado: (2013)

N‐terminal alterations turn the gut hormone GLP‐2 into an antagonist with gradual loss of GLP‐2 receptor selectivity towards more GLP‐1 receptor interaction
por: Gabe, Maria Buur Nordskov, et al.
Publicado: (2022)

Serum levels of glucagon-like peptide (GLP)-1 and GLP-2 in patients with Hashimoto's thyroiditis
por: Jin, Yue, et al.
Publicado: (2015)

GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
por: Abdalqadir, Nyan, et al.
Publicado: (2022)

Novel agonist and antagonist radioligands for the GLP‐2 receptor. Useful tools for studies of basic GLP‐2 receptor pharmacology
por: Gadgaard, Sarina, et al.
Publicado: (2022)

Global trends in the research and development of medical/pharmaceutical wastewater treatment over the half-century
por: Wang, Ling, et al.
Publicado: (2023)

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Madsen, Mette Simone Aae, et al.
Publicado: (2019)

GLP2-GLP2R signal affects the viability and EGFR-TKIs sensitivity of PC9 and HCC827 cells
por: Song, Bin, et al.
Publicado: (2022)

Gut HIF2α signaling is increased after VSG, and gut activation of HIF2α decreases weight, improves glucose, and increases GLP-1 secretion
por: Evers, Simon S., et al.
Publicado: (2022)

PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins
por: Schlapschy, Martin, et al.
Publicado: (2013)

Ultrastructural Study on Colocalization of Glucagon-Like Peptide (GLP)-1 with GLP-2 in Chicken Intestinal L-Cells
por: NISHIMURA, Kei, et al.
Publicado: (2013)

[Gly²]-GLP-2, But Not Glucagon or [D-Ala²]-GLP-1, Controls Collagen Crosslinking in Murine Osteoblast Cultures
por: Mieczkowska, Aleksandra, et al.
Publicado: (2021)

GLP-2 cures the gut – What about the liver?
por: Pakarinen, Mikko P.
Publicado: (2019)

Glucagon-like peptide 1 (GLP-1)
por: Müller, T.D., et al.
Publicado: (2019)

Half-and-half nails
por: Gandhi, K., et al.
Publicado: (2014)

Half and half nails
por: Neild, G. H., et al.
Publicado: (2011)

Half and half nail
por: Avhad, Ganesh, et al.
Publicado: (2014)

Half-and-Half Palatoplasty
por: Han, Hyun Ho, et al.
Publicado: (2014)

Simultaneous analyses of carbohydrate-mediated serum GLP-1 and GLP-2 and duodenal receptor expression in children with and without celiac disease
por: Rachmiel, Marianna, et al.
Publicado: (2019)

Distinct Identity of GLP-1R, GLP-2R, and GIPR Expressing Cells and Signaling Circuits Within the Gastrointestinal Tract
por: Morrow, Nadya M., et al.
Publicado: (2021)

Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors
por: Cattaruzza, Fiore, et al.
Publicado: (2023)

Systematic review: treatment pattern and clinical effectiveness and safety of pharmaceutical therapies for Crohn’s disease in Europe
por: Lelli, Filippo, et al.
Publicado: (2016)

Protective potential of glucagon like peptide 2 (GLP-2) against the neurodegeneration
por: Amato, Antonella, et al.
Publicado: (2019)

Glucagon-like peptide 2 (GLP-2) in bovine colostrum and transition milk
por: Inabu, Yudai, et al.
Publicado: (2021)

THU263 Intestinal Production of H(2)S And Its Regulation Of GLP-2
por: Hammond, Joel, et al.
Publicado: (2023)

Low-Dose Computed Tomography for the Optimization of Radiation Dose Exposure in Patients with Crohn's Disease
por: Kavanagh, Richard G., et al.
Publicado: (2018)

Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc
por: Yang, Yi, et al.
Publicado: (2016)

Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chia, Chee W, et al.
Publicado: (2009)

QCD meeting 2nd half 1988
por: Settles, R
Publicado: (1989)

Cannot write session to /tmp/vufind_sessions/sess_6lktocmvval94em8et0mo8nptl